Funding for medical research and Thank You Day campaign launch
13 October, 2005 by Susan WilliamsonThe latest commonwealth government funding announcement for health and medical research will see AUD$292 million allocated to more than 600 projects across 52 Australian universities, hospitals and medical research institutes.
Avantogen signs license agreement with Hawaii Biotech
12 October, 2005 by Helen SchullerAvantogen (ASX:ACU), formerly Australian Cancer Technology, has signed a worldwide, nonexclusive license agreement with Hawaii Biotech to evaluate Avantogen's proprietary adjuvant GPI-0100 with a series of vaccines.
Anadis to sell Travelan in USA
12 October, 2005 by Ruth BeranMelbourne biopharmaceutical company Anadis (ASX:ANX) has received legal advice that its over-the-counter traveller's diarrhoea product, Travelan, complies with all US federal and state regulations for sale in the dietary and medical foods categories.
AtCor Medical to list on ASX in November
12 October, 2005 by Ruth BeranSydney-based devices company AtCor Medical has lodged its prospectus for an initial public offering (IPO) to raise AUD$15 million for expanding the US marketing and sales of its cardiovascular diagnostic device, SphygmoCor.
Starpharma secures full ownership of VivaGel technology
11 October, 2005 by Helen SchullerMelbourne drug developer Starpharma (ASX:SPL) has acquired outright ownership of its VivaGel technology following changes to licence arrangements that were executed when Starpharma was spun-out of the Biomolecular Research Institute (BRI) in 1996.
Solbec's managing director resigns
11 October, 2005 by Ruth BeranPerth-based Solbec Pharmaceuticals' (ASX:SBP ) managing director, Stephen Carter, has resigned.
SciGen signs US$145m hep B distribution deal
10 October, 2005 by Helen SchullerSingapore-based generics company SciGen (ASX:SIE) has signed a Chinese distribution agreement worth at least US$145 million (AUD$191.6 million) with Hefei Life Science Park Investment & Development (HID) for its hepatitis B product, Sci-B-Vac.
Medical Developments International appoints new CEO
10 October, 2005 by Ruth BeranMelbourne-based Medical Developments International (ASX:MVP, MDI) has appointed Dr Simon Fisher as its new CEO, starting today.
In brief: Circadian, Metabolic, Mesoblast
07 October, 2005 by Ruth BeranAfter 21 years as Circadian's (ASX:CIR) founding chairman Sir Peter Derham retired at the conclusion of the company's AGM yesterday. Circadian managing director Leon Serry said that Sir Peter was stepping down because he's now 80 years of age.
SCS signs with Chemicon
07 October, 2005 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) has signed an exclusive agreement with Californian-based stem cells solutions provider Chemicon International, a wholly owned subsidiary of Serologicals Corporation (NASDAQ:SERO), for the manufacture and marketing of SCS' embryonic stem (ES) cell media to the research and drug discovery market.
pSivida secures US$15m, US Medicare rebate approved
07 October, 2005 by Helen SchullerpSivida has secured US$15 million (AUD$20 million) in additional funding from a New York institutional investor to assist in the development of its platform technology BioSilicon.
In brief: NeuroSolutions, Benitec, Living Cell Technologies, Chemgenex, Life Therapeutics
06 October, 2005 by Helen Schuller and Ruth BeranUK-based NeuroSolutions, the fully owned subsidiary of NeuroDiscovery (ASX:NDL), has signed its first Australian revenue contract with Perth-based biopharmaceutical company Alzhyme. NeuroSolutions' Alzheimer models will be used to investigate the potential of three Alzhyme peptides to impede the progression of the disease.
Peptech appoints new CEO
06 October, 2005 by Ruth BeranSydney's Peptech (ASX:PTD) has appointed Dr John Chiplin as its new chief executive officer, effective January 2006.
EvoGenix to optimise proteins for GlaxoSmithKline
06 October, 2005 by Ruth BeranGlaxoSmithKline (GSK) and EvoGenix (ASX:EGX) have signed a deal to apply the antibody developer's EvoGene technology to optimise selected compounds from GSK's product pipeline.
Starpharma awarded landmark contract for VivaGel development
05 October, 2005 by Helen SchullerMelbourne drug developer Starpharma (ASX:SPL) has been awarded a US$20.3 million (AUD$26.4 million) contract from the US National Institutes of Health (NIH), for the development of its HIV preventative product VivaGel.
